NYSEAMERICAN:BTX - BioTime Stock Price, Price Target & More

$2.36 -0.02 (-0.84 %)
(As of 04/20/2018 12:37 PM ET)
Previous Close$2.38
Today's Range$2.32 - $2.43
52-Week Range$2.10 - $3.50
Volume140,455 shs
Average Volume489,710 shs
Market Capitalization$338.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96

About BioTime (NYSEAMERICAN:BTX)

BioTime logoBioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSEAMERICAN:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins828.55%
Return on Equity30.68%
Return on Assets27.02%

Miscellaneous

EmployeesN/A
Outstanding Shares126,870,000

How to Become a New Pot Stock Millionaire

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) released its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.02. The biotechnology company had revenue of $1 million for the quarter, compared to the consensus estimate of $2.38 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for BioTime.

What price target have analysts set for BTX?

2 Wall Street analysts have issued 1 year price targets for BioTime's shares. Their predictions range from $6.50 to $8.00. On average, they expect BioTime's stock price to reach $7.25 in the next year. View Analyst Ratings for BioTime.

Are investors shorting BioTime?

BioTime saw a increase in short interest in March. As of March 29th, there was short interest totalling 8,258,973 shares, an increase of 2.4% from the March 15th total of 8,065,825 shares. Based on an average trading volume of 672,027 shares, the days-to-cover ratio is presently 12.3 days. Currently, 6.6% of the company's shares are sold short.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Dr. Michael D. West, Co-CEO & Director (Age 65)
  • Mr. Aditya P. Mohanty, Co-CEO, Pres & Director (Age 51)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Dan L. Lawrence, Director of Investor Relations & Corp. Communications
  • Dr. Stephana E. Patton Ph.D., J.D., Gen. Counsel and Corp. Sec. (Age 47)

Has BioTime been receiving favorable news coverage?

Media stories about BTX stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTime earned a daily sentiment score of 0.06 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $2.37.

How big of a company is BioTime?

BioTime has a market capitalization of $338.75 million.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (BTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioTime (NYSEAMERICAN:BTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for BioTime in the last 12 months. Their average twelve-month price target is $7.25, suggesting that the stock has a possible upside of 207.20%. The high price target for BTX is $8.00 and the low price target for BTX is $6.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.25$6.8333$6.25$6.25
Price Target Upside: 207.20% upside124.04% upside106.27% upside106.27% upside

BioTime (NYSEAMERICAN:BTX) Consensus Price Target History

Price Target History for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN:BTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/2/2018Lake Street CapitalInitiated CoverageBuy -> Buy$8.00View Rating Details
6/19/2017Ladenburg ThalmannReiterated RatingBuy$6.00 -> $6.50View Rating Details
3/31/2017Raymond JamesInitiated CoverageOutperform -> Outperform$6.00View Rating Details
(Data available from 4/20/2016 forward)

Earnings

BioTime (NYSEAMERICAN:BTX) Earnings History and Estimates Chart

Earnings by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.08)N/AView Earnings Details
3/15/2018Q4 2017($0.06)($0.08)$2.38 million$1.00 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.09)($0.05)$1.69 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.09)($0.05)$0.38 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.09)($0.08)$0.39 millionViewN/AView Earnings Details
11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.18)$2.31 millionViewN/AView Earnings Details
8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
3/11/2015Q4 2014($0.14)$1.89 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.6145 million$1.07 millionViewN/AView Earnings Details
3/17/2014Q4 2013($0.35)$1.89 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)$0.71 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.14)$1.22 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.15)$0.61 millionViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
11/9/2012Q3 2012($0.10)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.11)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.10)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.10)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.08)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.09)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.07)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.06)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.06)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/10/2010Q4 2009$0.06ViewN/AView Earnings Details
11/24/2009Q3 2009($0.11)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.07)ViewN/AView Earnings Details
5/19/2008Q1 2008($0.02)ViewN/AView Earnings Details
4/15/2008Q4 2007($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioTime (NYSEAMERICAN:BTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioTime (NYSEAMERICAN BTX) Insider Trading and Institutional Ownership History

Insider Trading History for BioTime (NYSEAMERICAN:BTX)
Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/13/2017Broadwood Partners, L.P.DirectorBuy2,692,307$2.60$6,999,998.20View SEC Filing  
8/23/2017Russell SkibstedCFOBuy2,000$2.64$5,280.00View SEC Filing  
8/22/2017Broadwood Partners, L.P.DirectorBuy10,000$2.60$26,000.00View SEC Filing  
8/22/2017Michael D. WestCEOBuy2,000$2.60$5,200.00View SEC Filing  
8/21/2017Aditya P. MohantyCEOBuy7,500$2.50$18,750.00View SEC Filing  
8/21/2017Deborah J AndrewsDirectorBuy2,396$2.50$5,990.008,396View SEC Filing  
7/31/2017Broadwood Partners, L.P.DirectorBuy150,000$2.80$420,000.00View SEC Filing  
6/16/2017Deborah J AndrewsDirectorBuy2,000$2.95$5,900.006,000View SEC Filing  
5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.004,000View SEC Filing  
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.005,938,055View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.0097,450View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.002,000View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioTime (NYSEAMERICAN BTX) News Headlines

Source:
DateHeadline
ValuEngine Downgrades BioTime (BTX) to SellValuEngine Downgrades BioTime (BTX) to Sell
www.americanbankingnews.com - April 19 at 2:58 PM
BioTime, Inc. (BTX) Receives Average Rating of "Hold" from AnalystsBioTime, Inc. (BTX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 9:40 AM
BidaskClub Downgrades BioTime (BTX) to Strong SellBidaskClub Downgrades BioTime (BTX) to Strong Sell
www.americanbankingnews.com - April 16 at 8:40 PM
and Retinal Restoration Programs to Be Presented at ARVO 2018and Retinal Restoration Programs to Be Presented at ARVO 2018
www.businesswire.com - April 16 at 8:43 AM
Form 4 BIOTIME INC For: Apr 10 Filed by: MOHANTY ADITYA P.Form 4 BIOTIME INC For: Apr 10 Filed by: MOHANTY ADITYA P.
www.streetinsider.com - April 13 at 3:22 PM
Form 4 BIOTIME INC For: Apr 10 Filed by: WEST MICHAEL DForm 4 BIOTIME INC For: Apr 10 Filed by: WEST MICHAEL D
www.streetinsider.com - April 13 at 3:22 PM
BioTime (BTX) Stock Rating Lowered by TheStreetBioTime (BTX) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - April 11 at 9:21 AM
Short Interest in BioTime, Inc. (BTX) Increases By 2.4%Short Interest in BioTime, Inc. (BTX) Increases By 2.4%
www.americanbankingnews.com - April 10 at 6:56 PM
Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation SummitProgram to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
www.businesswire.com - April 10 at 8:39 AM
BioTime (BTX): Moving Average Crossover AlertBioTime (BTX): Moving Average Crossover Alert
finance.yahoo.com - April 10 at 8:39 AM
Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation SummitData from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
finance.yahoo.com - April 9 at 3:23 PM
BioTime (BTX) Downgraded by BidaskClub to "Strong Sell"BioTime (BTX) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - April 6 at 7:00 PM
Free Research Reports on These Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTimeFree Research Reports on These Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTime
www.prnewswire.com - March 28 at 8:10 AM
BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance BiotechnologyBioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance Biotechnology
www.streetinsider.com - March 27 at 7:19 AM
BioTime Announces Cash Sale of Ascendance BiotechnologyBioTime Announces Cash Sale of Ascendance Biotechnology
finance.yahoo.com - March 27 at 7:19 AM
BioTime, Inc. (BTX) Short Interest Up 1.9% in MarchBioTime, Inc. (BTX) Short Interest Up 1.9% in March
www.americanbankingnews.com - March 26 at 6:54 PM
BioTime, Inc. (BTX) Given Average Rating of "Hold" by BrokeragesBioTime, Inc. (BTX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 9:52 AM
Zacks Investment Research Lowers BioTime (BTX) to Strong SellZacks Investment Research Lowers BioTime (BTX) to Strong Sell
www.americanbankingnews.com - March 22 at 6:54 PM
Edited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 3:17 PM
BioTime Reports Fourth Quarter and Fiscal 2017 Results | Business ... - Business Wire (press release)BioTime Reports Fourth Quarter and Fiscal 2017 Results | Business ... - Business Wire (press release)
www.businesswire.com - March 16 at 7:25 AM
BioTime Reports Fourth Quarter and Fiscal 2017 ResultsBioTime Reports Fourth Quarter and Fiscal 2017 Results
finance.yahoo.com - March 16 at 7:25 AM
BioTime reports 4Q lossBioTime reports 4Q loss
finance.yahoo.com - March 16 at 7:25 AM
BioTime, Inc. (AMEX:BTX) - BioTime Q4 Earnings Outlook | Benzinga - BenzingaBioTime, Inc. (AMEX:BTX) - BioTime Q4 Earnings Outlook | Benzinga - Benzinga
www.benzinga.com - March 15 at 3:22 PM
BioTime Q4 Earnings OutlookBioTime Q4 Earnings Outlook
finance.yahoo.com - March 15 at 3:22 PM
BioTime, Inc. to Host Earnings CallBioTime, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 3:22 PM
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in SessionBioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
finance.yahoo.com - March 14 at 3:20 PM
BioTime Submits CE Mark Application for European Approval of ... - Business Wire (press release)BioTime Submits CE Mark Application for European Approval of ... - Business Wire (press release)
www.businesswire.com - March 13 at 3:25 PM
BioTime Submits CE Mark Application for European Approval of Renevia®BioTime Submits CE Mark Application for European Approval of Renevia®
finance.yahoo.com - March 13 at 3:25 PM
BioTime, Inc. (BTX) Short Interest UpdateBioTime, Inc. (BTX) Short Interest Update
www.americanbankingnews.com - March 9 at 6:22 PM
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen - Business Wire (press release)BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen - Business Wire (press release)
www.businesswire.com - March 9 at 6:16 AM
BioTime advances clinical trial of OpRegen in dry AMD - BioTime ... - Seeking AlphaBioTime advances clinical trial of OpRegen in dry AMD - BioTime ... - Seeking Alpha
seekingalpha.com - March 7 at 3:17 PM
BioTime (BTX) Set to Announce Earnings on WednesdayBioTime (BTX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:32 AM
BioTime to Announce Fourth Quarter and Fiscal 2017 Results on ... - Business Wire (press release)BioTime to Announce Fourth Quarter and Fiscal 2017 Results on ... - Business Wire (press release)
www.businesswire.com - March 5 at 3:29 PM
BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
finance.yahoo.com - March 5 at 3:29 PM
AgeX Therapeutics CEO Dr. Michael D. West to Present at Three ... - Business Wire (press release)AgeX Therapeutics CEO Dr. Michael D. West to Present at Three ... - Business Wire (press release)
www.businesswire.com - March 1 at 3:17 PM
AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018
finance.yahoo.com - March 1 at 3:16 PM
BioTime to Present at the Raymond James 39th Annual Institutional ... - Business Wire (press release)BioTime to Present at the Raymond James 39th Annual Institutional ... - Business Wire (press release)
www.businesswire.com - March 1 at 7:58 AM
BioTime to Present at the Raymond James 39th Annual Institutional Investor ConferenceBioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
finance.yahoo.com - February 28 at 3:24 PM
BioTimes Dry AMD Product OpRegen: A Look At Trial Data - Seeking AlphaBioTime's Dry AMD Product OpRegen: A Look At Trial Data - Seeking Alpha
seekingalpha.com - February 28 at 6:37 AM
BioTime, Inc. (BTX) Short Interest Up 13.4% in FebruaryBioTime, Inc. (BTX) Short Interest Up 13.4% in February
www.americanbankingnews.com - February 27 at 5:58 PM
A Look At BioTime: Part 1 - Introduction And Renevia - Seeking AlphaA Look At BioTime: Part 1 - Introduction And Renevia - Seeking Alpha
seekingalpha.com - February 27 at 3:20 PM
BioTime, Inc. (BTX) Receives Average Rating of "Hold" from BrokeragesBioTime, Inc. (BTX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 12:08 PM
BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD ... - Business Wire (press release)BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD ... - Business Wire (press release)
www.businesswire.com - February 26 at 3:13 PM
BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical AffairsBioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
finance.yahoo.com - February 26 at 7:31 AM
BioTime Appoints Cavan Redmond to Its Board of Directors - Business Wire (press release)BioTime Appoints Cavan Redmond to Its Board of Directors - Business Wire (press release)
www.businesswire.com - February 22 at 7:27 AM
BioTime Appoints Cavan Redmond to Its Board of DirectorsBioTime Appoints Cavan Redmond to Its Board of Directors
finance.yahoo.com - February 22 at 7:27 AM
BioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies - Seeking AlphaBioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies - Seeking Alpha
seekingalpha.com - February 21 at 3:22 PM
and Vision Restoration Programs to Be Presented at ARVO 2018 - Business Wire (press release)and Vision Restoration Programs to Be Presented at ARVO 2018 - Business Wire (press release)
www.businesswire.com - February 15 at 3:19 PM
Data from BioTimes OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
finance.yahoo.com - February 15 at 3:19 PM
BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12 - Business Wire (press release)BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12 - Business Wire (press release)
www.businesswire.com - February 7 at 3:15 PM

SEC Filings

BioTime (NYSEAMERICAN:BTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioTime (NYSEAMERICAN:BTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioTime (NYSEAMERICAN BTX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.